Literature DB >> 29247767

Implications of melanin binding in ocular drug delivery.

Anna-Kaisa Rimpelä1, Mika Reinisalo2, Laura Hellinen2, Evgeni Grazhdankin1, Heidi Kidron1, Arto Urtti3, Eva M Del Amo4.   

Abstract

Pigmented ocular tissues contain melanin within the intracellular melanosomes. Drugs bind to melanin at varying extent that ranges from no binding to extensive binding. Binding may lead to drug accumulation to the pigmented tissues and prolonged drug retention in the melanin containing cells. Therefore, melanin binding is an important feature that affects ocular drug delivery and biodistribution, but this topic has not been reviewed since 1998. In this review, we present current knowledge on ocular melanin, melanosomes and binding of drugs to pigmented cells and tissues. In vitro, in vivo and in silico methods in the field were critically evaluated, because the literature in this field can be confusing if the reader does not properly understand the methodological aspects. Literature analysis includes a comprehensive table of literature data on melanin binding of drugs. Furthermore, we aimed to give some insights beyond the current literature by making a chemical structure based classification model for melanin binding of drugs and kinetic simulations that revealed significant interplay between melanin binding and drug permeability across the melanosomal and plasma membranes. Overall, more mechanistic and systematic research is needed before the impact of melanin binding on ocular drug delivery can be properly understood and predicted.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Melanosomes; Ocular melanin; Pharmacodynamics; Pharmacokinetic simulations; Pharmacokinetics; Pigment binding; QSAR

Mesh:

Substances:

Year:  2017        PMID: 29247767     DOI: 10.1016/j.addr.2017.12.008

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  19 in total

1.  Application of Mechanistic Ocular Absorption Modeling and Simulation to Understand the Impact of Formulation Properties on Ophthalmic Bioavailability in Rabbits: a Case Study Using Dexamethasone Suspension.

Authors:  Maxime Le Merdy; Jianghong Fan; Michael B Bolger; Viera Lukacova; Jessica Spires; Eleftheria Tsakalozou; Vikram Patel; Lin Xu; Sharron Stewart; Ashok Chockalingam; Suresh Narayanasamy; Rodney Rouse; Murali Matta; Andrew Babiskin; Darby Kozak; Stephanie Choi; Lei Zhang; Robert Lionberger; Liang Zhao
Journal:  AAPS J       Date:  2019-05-20       Impact factor: 4.009

2.  Noninvasive two-photon optical biopsy of retinal fluorophores.

Authors:  Grazyna Palczewska; Jakub Boguslawski; Patrycjusz Stremplewski; Lukasz Kornaszewski; Jianye Zhang; Zhiqian Dong; Xiao-Xuan Liang; Enrico Gratton; Alfred Vogel; Maciej Wojtkowski; Krzysztof Palczewski
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-26       Impact factor: 11.205

Review 3.  Ocular barriers as a double-edged sword: preventing and facilitating drug delivery to the retina.

Authors:  Lixiang Wang; Hui Zhang
Journal:  Drug Deliv Transl Res       Date:  2022-09-21       Impact factor: 5.671

4.  A hypotonic gel-forming eye drop provides enhanced intraocular delivery of a kinase inhibitor with melanin-binding properties for sustained protection of retinal ganglion cells.

Authors:  Yoo Chun Kim; Henry T Hsueh; Matthew D Shin; Cynthia A Berlinicke; Hyounkoo Han; Nicole M Anders; Avelina Hemingway; Kirby T Leo; Renee Ti Chou; HyeYoung Kwon; Matthew B Appell; Usha Rai; Patricia Kolodziejski; Charles Eberhart; Ian Pitha; Donald J Zack; Justin Hanes; Laura M Ensign
Journal:  Drug Deliv Transl Res       Date:  2021-04-26       Impact factor: 4.617

Review 5.  Peptidomimetics Therapeutics for Retinal Disease.

Authors:  Dylan E Parsons; Soo Hyeon Lee; Young Joo Sun; Gabriel Velez; Alexander G Bassuk; Mark Smith; Vinit B Mahajan
Journal:  Biomolecules       Date:  2021-02-24

6.  Characterization of artificially re-pigmented ARPE-19 retinal pigment epithelial cell model.

Authors:  Laura Hellinen; Marja Hagström; Heidi Knuutila; Marika Ruponen; Arto Urtti; Mika Reinisalo
Journal:  Sci Rep       Date:  2019-09-24       Impact factor: 4.379

Review 7.  Melanins as Sustainable Resources for Advanced Biotechnological Applications.

Authors:  Hanaa A Galeb; Emma L Wilkinson; Alison F Stowell; Hungyen Lin; Samuel T Murphy; Pierre L Martin-Hirsch; Richard L Mort; Adam M Taylor; John G Hardy
Journal:  Glob Chall       Date:  2020-11-25

8.  Ion-Complex Microcrystal Formulation Provides Sustained Delivery of a Multimodal Kinase Inhibitor from the Subconjunctival Space for Protection of Retinal Ganglion Cells.

Authors:  Henry T Hsueh; Yoo-Chun Kim; Ian Pitha; Matthew D Shin; Cynthia A Berlinicke; Renee Ti Chou; Elizabeth Kimball; Julie Schaub; Sarah Quillen; Kirby T Leo; Hyounkoo Han; Amy Xiao; Youngwook Kim; Matthew Appell; Usha Rai; HyeYoung Kwon; Patricia Kolodziejski; Laolu Ogunnaike; Nicole M Anders; Avelina Hemingway; Joan L Jefferys; Abhijit A Date; Charles Eberhart; Thomas V Johnson; Harry A Quigley; Donald J Zack; Justin Hanes; Laura M Ensign
Journal:  Pharmaceutics       Date:  2021-05-01       Impact factor: 6.321

9.  Ocular Physiologically Based Pharmacokinetic Modeling for Ointment Formulations.

Authors:  Maxime Le Merdy; Jessica Spires; Viera Lukacova; Ming-Liang Tan; Andrew Babiskin; Xiaoming Xu; Liang Zhao; Michael B Bolger
Journal:  Pharm Res       Date:  2020-11-19       Impact factor: 4.200

10.  Drug Flux Across RPE Cell Models: The Hunt for An Appropriate Outer Blood-Retinal Barrier Model for Use in Early Drug Discovery.

Authors:  Laura Hellinen; Heidi Hongisto; Eva Ramsay; Kai Kaarniranta; Kati-Sisko Vellonen; Heli Skottman; Marika Ruponen
Journal:  Pharmaceutics       Date:  2020-02-19       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.